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Abstract
Background: KRAS mutations are common in colorectal cancer (CRC). The role of KRAS mutation status as a
prognostic factor remains controversial, and most large population-based cohorts usually consist of patients with
non-metastatic CRC. We evaluated the impact of KRAS mutations on the time to recurrence (TTR) and overall
survival (OS) in patients with metastatic CRC who underwent curative surgery with perioperative chemotherapy.
Methods: Patients who underwent curative resection for primary and synchronous metastases were retrospectively
collected in a single institution during a 6 year period between January 2008 and June 2014. Patients with positive
surgical margins, those with known BRAF mutation, or those with an unknown KRAS mutation status were excluded,
and a total of 82 cases were identified. The pathological and clinical features were evaluated. Patients’ outcome
with KRAS mutation status for TTR and OS were investigated by univariate and multivariate analysis.
Results: KRAS mutations were identified in 37.8 % of the patients and not associated with TTR or OS between KRAS
wild type and KRAS mutation cohorts (log-rank p = 0.425 for TTR; log-rank p = 0.137 for OS). When patients were
further subdivided into three groups according to mutation subtype (wild-type vs. KRAS codon 12 mutation vs.
KRAS codon 13 mutation) or amino acid missense mutation type (G > A vs. G > T vs. G > C), there were no
significant differences in TTR or OS. Mutational frequencies were significantly higher in patients with lung
metastases compared with those with liver and ovary/bladder metastases (p = 0.039), however, KRAS mutation
status was not associated with an increased risk of relapsed in the lung.
Conclusions: KRAS mutation was not associated with TTR or OS in patients with metastatic CRC who underwent
curative surgery with perioperative chemotherapy.
Keywords: Colorectal cancer, KRAS mutation, Prognosis, Metastases
* Correspondence: hc111.kim@samsung.com; psy27hmo.park@samsung.com
Hae Su Kim and Jin Seok Heo are co-first author
†Equal contributors
2Surgery, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea
1Division of Hematology-Oncology, Department of Medicine, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Full list of author information is available at the end of the article
© 2016 Kim et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. BMC Cancer  (2016) 16:120 
DOI 10.1186/s12885-016-2141-4
Background
Colorectal cancer (CRC) is the fourth leading cause of
cancer-related death worldwide [1]. Although the devel-
opment of molecular-targeted therapy has improved the
survival of patients with metastatic CRC [2, 3], the ma-
jority of patients with stage IV CRC who undergo
complete resection die from metastatic disease. Never-
theless, a good proportion of patients demonstrate good
recurrence-free survival. CRC tumorigenesis is charac-
terized by the accumulation of genetic alterations, and
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutations are an early event in tumorigenesis
[4]. KRAS mutations occur in approximately 30 to 40 %
of patients with CRC, and 90 % of KRAS mutations
occur in codon 12 or 13 [2, 5, 6]. KRAS mutations lead
to constitutive activation of downstream pathways, in-
cluding the Ras/Raf/MAP/MEK/ERK and/or PTEN/
PI3K/Akt pathways [7–10]. KRAS mutations are estab-
lished biomarkers for predicting the poor efficacy of
anti-epidermal growth factor receptor (EGFR) monoclo-
nal antibodies in patients with stage IV CRC [2, 5, 11],
but the prognostic relevance of KRAS mutations remains
controversial [12–16]. Recent studies, in patients with
resected stage II and/or III CRC, have highlighted the
prognostic value of KRAS codon12 and 13 mutations,
showing correlations between mutation subtype, cancer
recurrence, and poor overall survival [13–15].
Large population-based cohorts usually consist of pa-
tients with non-metastatic CRC [12, 14, 16, 17]. The
prognostic impact of KRAS mutation in patients with
synchronous metastatic CRC who undergo curative re-
section with perioperative chemotherapy is unknown.
The current study investigated the impact of KRAS mu-
tations on the time to recurrence (TTR) and overall sur-
vival (OS) in patients with stage IV CRC who underwent
curative surgery with perioperative chemotherapy. In
addition, the recurrence pattern according to KRAS mu-
tation status after complete resection was evaluated.
Methods
Patients
In this retrospective study, patients who underwent
curative resection for primary and synchronous metasta-
ses at our institution between January 2008 and June
2014 were identified from the hospital records. Patients
who underwent separate colorectal resection and metas-
tasectomy were excluded if the duration between the
two procedures exceeded 2 months. Patients with posi-
tive surgical margins, those with known v-Raf murine
sarcoma viral oncogene homolog B (BRAF) mutations,
or those with an unknown KRAS mutation status were
also excluded. All patients included in the study were ad-
ministered 5-FU with/without oxaliplatin or irinotecan-
based chemotherapy. Clinical and pathological data
including sex, patient age, tumor location, resection site,
staging at surgery (performed in accordance with the
classification of the 6th Edition of the American Joint
Committee on Cancer guidelines), BRAF mutation sta-
tus, perioperative chemotherapy regimens, use of mo-
lecular targeting agents including cetuximab and
bevacizumab, were collected. The study protocol was
reviewed and approved by the SMC institutional review
board.
Perioperative chemotherapy regimens
Oxaliplatin based chemotherapy was FOLFOX (oxalipla-
tin 85 mg/m2 on day 1, infused during 2 h; LV 200 mg/
m2, infused during 2 h, followed by 5-FU as a 400 mg/
m2 intravenous bolus then a 1200 mg/m2 infusion dur-
ing 22 h on days 1 and 2) in 2 week treatment cycles or
XELOX(oxaliplatin 130 mg/m2 on day 1 followed by oral
capecitabine 1000 mg/m2 twice daily (day 1 to 14) in
3 week treatment cycles. Irinotecan based chemotherapy
was FORFIRI (irinotecan 180 mg/m2 on day 1, infused
during 2 h; LV 200 mg/m2, infused during 2 h, followed
by 5-FU as a 400 mg/m2 intravenous bolus then a
1200 mg/m2 infusion during 22 h on days 1 and 2) in
2 week treatment cycles or XELIRI (irinotecan 250 mg/
m2 on day 1 followed by oral capecitabine 1000 mg/m2
twice daily (day 1 to 14) in 3 week treatment cycles. If
bevacizumab or cetuximab was used, patients received
cetuximab (initial dose 400 mg/m2 infused during 2 h,
and 250 mg/m2 weekly) or bevacizumab (5 mg/kg)
followed by FOLFOX or FOLFIRI.
DNA extraction and mutation analysis
DNA was isolated from 10-μm formalin-fixed, paraffin-
embedded tumor specimens using FFPE-DNA isolation
kit (Qiagen, Hilden, Germany). A Qiagen the rascreen
KRAS mutation kit was used to detect the seven most
common KRAS codon 12 and 13 mutations. Specifically,
the mutation was detected by real-time polymerase
chain reaction based on amplification-refractory muta-
tion system and Scorpion probes (Gly12Asp [GGT >
GAT] G12D, Gly12Val [GGT >GAC] G12V, Gly12Cys
[GGT > TGT] G12C, Gly12Ser [GGT > AGT] G12S,
Gly12Ala [GGT > GCT] G12A, Gly12Arg [GGT > CGT]
G12R, Gly13Asp [GGC >GAC] G13D).
Statistical analyses
Patients were subdivided into wild-type KRAS and mu-
tant KRAS cohorts. The primary objective was to investi-
gate the effect of KRAS mutation on the TTR. TTR was
defined as the time from the date of operation to the
date of local or metastatic recurrence. As of November
2014, overall survival data are not yet available for the
mutant KRAS group. Data from recurrence-free patients
were censored at the date of the last follow-up.
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(n = 82) (n = 51) (n = 31)
Age, year, Median (range) 55.8 (25–77) 58.8 (25–77) 55.5 (29–77) 0.565
≥65 years 17 (21 %) 12 (24 %) 5 (16 %) 0.423
Sex 0.867
Male 44 (54 %) 27 (53 %) 17 (55 %)
Female 38 (46 %) 24 (47 %) 14 (45 %)
Location 0.246
Colon 54 (66 %) 36 (71 %) 18 (58 %)
Rectum 28 (34 %) 15 (29 %) 13 (42 %)
Neoadjuvant Chemotherapy 21 (26 %) 11 (22 %) 10 (32 %) 0.282
Resection site 0.039
Liver 57 (69 %) 39 (76 %) 18 (58 %)
Lung 13 (16 %) 4 (8 %) 9 (29 %)
Others (ovary, bladder) 12 (15 %) 8 (16 %) 4 (13 %)
Tumor grade 0.432
Well 10 (12 %) 7 (14 %) 3 (10 %)
Moderate/Poor 72 (78 %) 44 (86 %) 28 (90 %)
T stage 0.265
T1 1 (1 %) 1 (2 %) 0 (0 %)
T2 2 (2 %) 2 (4 %) 0 (0 %)
T3 47 (57 %) 30 (59 %) 17 (55 %)
T4 30 (37 %) 18 (35 %) 12 (39 %)
Tx 2 (2 %) 0 (0 %) 2 (6 %)
N stage 0.824
N0 12 (15 %) 8 (16 %) 4 (13 %)
N1 31 (38 %) 18 (35 %) 13 (42 %)
N2 39 (47 %) 25 (49 %) 14 (45 %)
1st Adjuvant Chemo-Regimen 0.923
Oxaliplatin-based 70 (86 %) 44 (86 %) 26 (84 %)
Irinotecan-based 10 (12 %) 6 (12 %) 4 (13 %)
Only 5-FU 2 (2 %) 1 (2 %) 1 (3 %)
Use of Cetuximab at 1st post-operative chemotherapy 4 (5 %) 4 (8 %) 0 (0 %) NA
Use of Becavizumab at 1st post-operativechemotherapy 13 (16 %) 6 (12 %) 7 (23 %) 0.194
Ever use of Cetuximab 16 (20 %) 16 (31 %) 0 (0 %) NA
Ever use of Bevacizumab 23 (28 %) 10 (20 %) 13 (42 %) 0.029
Recurrence pattern (n = 57) 0.616
Primary site 3 (5 %) 1 (2 %) 2 (8 %)
Metastasectomy site 27 (47 %) 15 (46 %) 12 (50 %)
New distant sites 27 (47 %) 17 (52 %) 10 (42 %)
Duration of follow up month, median (range) 25 (4–74) 25 (4–74) 34 (9–63) 0.763
Abbreviations: CI confidence interval, A.A amino acid
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Fig. 1 Time to recurrence (a) and overall survival (b) according to KRAS status. KRAS mutation status had no impact on time to recurrence (p = 0.425)
and overall survival (p = 0.137)
Kim et al. BMC Cancer  (2016) 16:120 Page 4 of 8
To compare baseline characteristics, categorical out-
comes were analyzed using the chi-square test or Fisher’s
exact test. Continuous variables are presented as medians
and ranges. TTR and OS were calculated using the
Kaplan-Meier method, and data was compared using the
log-rank test. The Cox proportional hazard model was
used to assess hazard ratios (HRs) of prognostic factor. All
factors of statistical significance (p < 0.10) in univariate
analysis were included in the multivariate analysis.
Two-sided p values of <0.05 were considered as statisti-
cally significant. All statistical analyses were performed




Between January 2008 and June 2014, 82 patients who
were diagnosed with synchronous metastatic CRC and
underwent curative resection of primary and metastatic
lesions with perioperative chemotherapy were included
in the analyses. Table 1 summarizes the patient
characteristics according to KRAS mutation status.
There was no significant difference in clinicopatho-
logic features between the two groups. Baseline char-
acteristics including age, sex, tumor location, tumor
grade, T stage, N stage, synchronous metastasectomy
site, and recurrence site were similar between the
KRAS wild type and KRAS mutation cohorts. Regard-
ing BRAF mutation status, all of the tested cases
(76.8 %) were BRAF wild type.
Subtype of KRAS mutations
Of 82 patients, KRAS mutations were detected in 31
(37.8 %) patients. Eighteen (58 %) patients harbored
codon 12 mutations including 9 with c.35G > A (p.G12D,
codon 12 GGT >GAT), 5 with c.35G > T (pG12V, codon
12 GGT >GTT), 2 with c.35G > C (p.G12A, codon 12
GGT >GCT), and 2 with c.34G > A (p.G12S, codon 12
GGT >AGT). For the 13 (42 %) patients with codon 13
mutations, all had the c.38G > A (p.G13D, codon 13
GGC >GAC) mutation. KRAS amino acid mutations were
also analyzed. The G > A missense mutation was the most
Table 2 Univariate analysis for time to recurrence
Characteristics Hazard ratio (95 % CI) p-value
Location of primary tumor (rectum vs colon) 0.956 (0.548–1.669) 0.875
Age (≥65 vs <65) 0.856 (0.418–1.755) 0.671
Sex (female vs male) 0.678 (0.399–1.150) 0.150
Neoadjuvant chemotherapy (Yes vs No) 1.040 (0.563–1.923) 0.899
Tumor grade (moderate/poor vs well) 1.201 (0.508–2.843) 0.676
T stage (T4 vs T1-3) 1.041 (0.608–1.782) 0.885
N stage (N2 vs N0,1) 1.197 (0.703–2.037) 0.508
Resection site
Liver 1
Lung 0.694 (0.311–1.550) 0.373
Others (ovary, uterus, bladder) 0.670 (0.299–1.502) 0.331
Use of Cetuximab at 1st post-operative chemotherapy (Yes vs No) 0.589 (0.143–2.425) 0.463
Use of Bevacizumab at 1st post-operative chemotherapy (Yes vs No) 0.582 (0.231–1.469) 0.252
KRAS (mutation vs wild) 1.245 (0.725–2.137) 1.245
KRAS subtype
Wild 1
12th 1.127 (0.599–2.123) 0.710
13th 1.230 (0.561–2.697) 0.605
A.A Mutation type
Wild (n = 51) 1
Guanine to thymidine (n = 5) 0.737 (0.164–3.315) 0.691
Guanine to cytosine (n = 2) 1.482 (0.766–2.864) 0.242
Guanine to adenine (n = 24) 1.029 (0.553–1.931) 0.928
Abbreviations: CI confidence interval, A.A amino acid, HR hazard ratio
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frequently observed mutation, followed by the G > T and
G >C mutations.
The impact of KRAS mutations on TTR and OS
The median follow-up durations were 25 months (range,
4–74) and 34 months (range, 9–63) for patients with KRAS
wild type and KRAS mutation status, respectively. During
follow-up in surviving participants, there were 57 events
for TTR analysis and 25 events for OS analysis. There were
no significant differences in survival time distributions ac-
cording to KRAS wild type and KRAS mutation status (log-
rank p = 0.425 for TTR; log-rank p = 0.137 for OS, Fig. 1).
In univariate and multivariate analyses, there were no sig-
nificant differences in TTR or OS between KRAS wild type
and KRAS mutation cohorts (Tables 2, 3 and 4). When pa-
tients were further subdivided into three groups according
to mutation subtype (wild-type vs. KRAS codon 12 muta-
tion vs. KRAS codon 13 mutation) or amino acid missense
mutation type (G >A vs. G > T vs. G >C), there were no
significant differences in TTR or OS.
The effect of KRAS mutation status on the recurrence site
Mutational frequencies were significantly higher in pa-
tients with lung metastases compared with those with
liver and ovary/bladder metastases (KRAS mutant: lung
9/13 [69 %], liver 18/57 [31 %], ovary/bladder 4/12
[33 %]; p = 0.039). However, KRAS mutation status was
not associated with an increased risk of relapse in the
lung, and the majority of recurrence occurred at the pre-
vious metastasectomy sites (15/33 vs. 24/31 for KRAS
wild type vs. KRAS mutation, respectively).
Discussion
The majority of studies evaluating the prognostic impact
of KRAS mutational status in CRC have been conducted
in patients with stage II/III disease. The QUASAR trial,
which mainly evaluated patients with stage II CRC, re-
vealed that KRAS mutations had a detrimental effect on
recurrence and OS, despite adjuvant chemotherapy [17].
In contrast, the CALGB 89803 and PETACC-3 trials
demonstrated that KRAS mutation status had no signifi-
cant effect on recurrence or OS in patients with stage II/
III colon cancer or CRC treated with adjuvant chemo-
therapy [12, 16]. However, conflicting findings were re-
ported simultaneously in two large studies conducted by
The Kirsten ras in-colorectal-cancer collaborative group,
the RASCAL and RASCAL II trials, which were com-
prised of 2721 and 4268 patients, respectively [18, 19].
Although the first RASCAL study reported an associ-
ation of KRAS mutations with an increased risk of recur-
rence and death for patients with all stages of CRC,
recurrence in patients with Dukes’ D tumors was less
than might be expected. The RASCAL II study con-
cluded that there was a significant prognostic value in
failure-free survival alone in patients with Dukes’ C can-
cer harboring a KRAS G12V mutation.
Table 3 Univariate analysis for overall survival
Characteristics HR (95 % CI) p-value
Location of primary tumor (rectum vs colon) 0.531 (0.212–1.333) 0.178
Age (≥65 vs <65) 7.492 (2.941–9.084) <0.001
Sex (female vs male) 2.038 (0.908–4.578) 0.085
Neoadjuvant chemotherapy (Yes vs No) 1.114 (0.460–2.698) 0.811
Tumor grade (moderate/poor vs well) 1.332 (0.312–5.693) 0.698
T stage (T4 vs T1-3) 4.324 (1.857–10.068) 0.001
N stage (N2 vs N0,1) 1.906 (0.854–4.251) 0.115
Resection site
Liver 1
Lung 0.311 (0.041–2.335) 0.256
Others (ovary, uterus, bladder) 1.036 (0.345–3.108) 0.950
Use of Cetuximab at 1st post-operative chemotherapy (Yes vs No) 3.777 (0.850–16.779) 0.081
Use of Bevacizumab at 1st post-operative chemotherapy (Yes vs No) 0.899 (0.267–3.027) 0.863
KRAS (mutation vs mutation) 0.500(0.198–1.267) 0.144
KRAS
Wild 1
12th 0.330 (0.076–1.428) 0.138
13th 0.675 (0.227–2.010) 0.481
Abbreviations: CI confidence interval, A.A amino acid, HR hazard ratio
Factors of statistical significance (p < 0.10) in univariate analysis presented with boldface
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Few studies have evaluated the relationship between
patients with stage IV disease at the time of diagnosis
and KRAS mutations [20–23]. Patients with metastatic
CRC with limited metastases undergo curative primary
resection with or without metastasectomy, anti-EGFR
antibody therapy, and heterogeneous chemotherapy regi-
mens, making it difficult to evaluate the precise prog-
nostic value of KRAS status in this setting. To overcome
this limitation, in this study, we included only patients
who underwent curative resection of the primary and
metastatic sites who received perioperative chemother-
apy. To our knowledge, this study is the first to report
TTR in such patients. In this homogenous cohort of
Korean patients with metastatic CRC, we observed that
KRAS mutation was not associated with TTR or OS,
which is congruent with previous studies [20–22].
Phipps et al., reported that KRAS mutations did not dif-
fer by stage at diagnosis, and that the prognostic value
of KRAS mutations only became evident in patients with
stage I-III disease [22]. Furthermore, Nash et al., re-
ported that the prevalence of KRAS mutations did not
vary with stage, but that KRAS mutations were strong
independent predictors of survival for patients with stage
I-III CRC [21].
We also investigated the association KRAS mutations
with recurrence pattern in our cohort. KRAS mutations
were significantly more common in lung metastases
compared with liver and bladder/ovary metastases.
These finding were concordant with those of Tie et al.,
who observed a significantly higher prevalence of KRAS
mutations in patients with lung metastases compared
with those with liver metastases [24]. In addition, in
their study, KRAS mutations were associated with an in-
creased risk of lung relapse in patients with stage II/III
CRC who were enrolled on the VICTOR clinical trial
[21]. However, in the present study, we did not observe
recurrence-specific associations with KRAS mutation
status. The differential impact of KRAS mutations on
recurrence-specific sites according to disease stage re-
quires evaluation in further studies.
Limitations of the present study included the relatively
short follow-up, where the median OS was not reached
in the KRAS mutation group. Nevertheless, sufficient
TTR events occured enabling analysis of recurrence. In
addition, the BRAF mutation status was not determined
for 19 (33 %) patients, but BRAF mutations were only
detected in a small proportion of patient and were not
significantly different between KRAS wild type and
KRAS mutated patients. In addition, the small sample
size did not allow us to evaluate the impact of different
KRAS mutation subtypes.
In conclusion, KRAS mutation was not associated with
TTR or OS in curatively resected, metastatic CRC. Fur-
ther validation of these finding is needed in metastatic
CRC patients treated with curative resection in prospect-
ive controlled trials.
Conclusions
The present study, to our knowledge, is the first report
on the effect of KRAS mutations on prognosis in surgi-
cally treated CRC patients with synchronous metastases.
The most of previous studies evaluating the prognostic
impact of KRAS in CRC have been conducted in pa-
tients with non-metastatic CRC, and the influence of
KRAS mutations on outcome is conflicting. In our study,
KRAS mutation was not associated with TTR or OS in
metastatic CRC patients who undergo curative surgery
and perioperative chemotherapy. KRAS mutation status
was also not linked to recurrence pattern. Prospective
studies will be necessary to evaluate the prognostic effect
of KRAS mutation in metastatic CRC patients.
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